| |
|
Product Name:
|
Human Immunodeficiency Virus 1 (HIV-1) MN-Infected H9 Cells
|
|
Manufacturer:
|
BEI Resources
|
|
Material Provided:
|
Each vial contains approximately 1.0 mL of frozen cells in RPMI 1640 supplemented with 40% fetal bovine serum and 10% dimethyl sulfoxide (DMSO). Sufficient cells are provided to initiate at least one new culture. The cell count, expressed as cells/vial, is shown on individual Certificates of Analysis for each lot.
|
|
Packing/Storage:
|
This product was packaged aseptically in cryovials. It should be stored at cryogenic temperature (-100°C or colder), preferably in the vapor phase of a liquid nitrogen freezer. Storage at -70°C will result in loss of viability. To ensure the highest level of viability, the vial should be thawed and the culture initiated as soon as possible upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product after thawing. For transfer between freezers and shipping, the cells may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to reconstituting this material.
|
|
Safety Precautions:
|
When handling frozen vials, it is highly recommended that protective gloves, lab coat and full-face mask be worn. Even brief exposure to the ultra-cold temperature can cause tissue damage from frostbite. Also, some vials may slowly fill with liquid nitrogen if they have been immersed during cryogenic storage. When thawing, the liquid nitrogen may rapidly expand as it changes to gas, breaking the vial or cap with explosive force, sending debris flying with enough velocity to cause injury. Store and use in areas with adequate ventilation
|
|
Thawing and Growth:
|
Prior to thawing the cells, prepare growth medium (GM) for use. HRP-402 is grown in RPMI 1640 supplemented with 10% fetal bovine serum.
Rapidly thaw the vial of cells in a 37°C water bath with gentle agitation. To reduce the risk of contamination, keep the cap and O-ring of the vial out of the water and repeatedly check the cap for tightness during thawing. Remove from the water bath immediately when thawed. Dry the vial with a sterile wiper, decontaminate using a
wiper soaked with 70% isopropyl alcohol, and let the vial air dry. Aseptically open the vial, remove the vial contents and add 4.0 mL of GM in a centrifuge tube. Centrifuge the cell suspension at 150 × g for
8 to 10 minutes at 18°C to 25°C. Discard the supernatant and resuspend the cell pellet in 10 mL of pre-warmed GM. Transfer the cell suspension into a 75 cm2 flask. Incubate the new culture at 37°C and 5% CO2.
Sub-culture procedure:
Cultures can be maintained by the addition of fresh GM or the replacement of GM. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2.0 × 105 cells/mL. Maintain a cell density between 1.0 × 106 and 1.2 × 106 cells/mL. To replace the GM, centrifuge the cell suspension at 150 to 300 × g for 8 to 10 minutes at 18°C to 25°C, remove the supernatant and resuspend the cell pellet in fresh pre-warmed complete GM to the desired cell density. Add fresh medium every 2 to 3 days, depending on cell density.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
|
Patents or other restrictions:
|
Scientists at for-profit institutions or who intend commercial use of this reagent must contact the National Cancer Institute's Technology Transfer Center at: NCITTCFREDERICK@mail.nih.gov before the reagent can be released. Please specify the name and a description of the intended use of the reagent.
|
References:
|
1. Gallo, R. C., et al. “Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS.” Science 224 (1984): 500-503. PubMed: 6200936.
2. Shaw, G. M., et al. “Molecular Characterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III in the Acquired Immune Deficiency Syndrome.” Science 226 (1984): 1165-1170. PubMed: 6095449.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Human Immunodeficiency Virus 1 (HIV-1) MN-Infected H9 Cells, HRP-402."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|